Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Kaufmann, 2006, International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: an update, J Clin Oncol, 23, 2600 von Minckwitz, 2006, Individualized treatment strategies according to in vivo chemosensitivity assessed by response after 2 cycles of neoadjuvant chemotherapy. Final results of the Gepartrio study of German Breast Group, Breast Cancer Res Treat Wenzel, 2005, Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer, Anticancer Drugs, 16, 441, 10.1097/00001813-200504000-00011 Schmid, 2005, Primary chemotherapy with gemcitabine, liposomal doxorubicin, docetaxel in patients with locally advanced breast cancer: results of a phase I trial, Anticancer Drugs, 16, 21, 10.1097/00001813-200501000-00003 Schneeweiss, 2004, Neoadjuvant therapy with gemcitabine in breast cancer, Oncology, 18, 27 Buzdar, 2007, Clin Cancer Res, 13, 228, 10.1158/1078-0432.CCR-06-1345 Torrisi, 2004, Endocrine and chemoendocrine primary therapy in premenopausal women with endocrine responsive breast cancer: a feasibility study, Breast Cancer Res Treat, 88 Torrisi, 2007, Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer Breast, 16, 73 Del Mastro, 2006, Prevention of chemotherapy–induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients, Ann Oncol, 17, 74, 10.1093/annonc/mdj029 Smith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double–blind randomized trial, J Clin Oncol, 23, 5108, 10.1200/JCO.2005.04.005 Domont, 2004, Is there an optimal duration of neoadjuvant letrozole therapy?, Breast Cancer Res Treat, 88 Mamounas, 2006, Neoadjuvant Chemotherapy in operable breast cancer, Breast Care, 1, 348, 10.1159/000097887 Ring, 2004, Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer, Br J Cancer, 91, 2012, 10.1038/sj.bjc.6602235 Colleoni, 2004, Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment, Clin Cancer Res, 10, 6622, 10.1158/1078-0432.CCR-04-0380 Hennessy, 2005, Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy, J Clin Oncol, 23, 9304, 10.1200/JCO.2005.02.5023 Wenzel, 2007, Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF, Breast Cancer Res Treat, 104, 109, 10.1007/s10549-006-9397-3 Tubiana-Hulin, 2006, Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution, Ann Oncol, 17, 1228, 10.1093/annonc/mdl114 Cristofanilli, 2005, Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes, J Clin Oncol, 23, 41, 10.1200/JCO.2005.03.111 Loibl, 2005, Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline / taxane based regimen in the multicenter GeparTrio trial, Breast Cancer Res Treat, 94 Bozzetti, 2006, Evaluation of Her–2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline–based chemotherapy in primary breast cancer: the role of anthracycline dose intensity, Am J Clin Oncol, 29, 171, 10.1097/01.coc.0000204405.96572.f9 Learn, 2005, Her–2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma, Cancer, 103, 2252, 10.1002/cncr.21037 MacGrogan, 2003, DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer, Br J Cancer, 89, 1179, 10.1038/sj.bjc.6601185 Rody, 2007, Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response, Breast, 16, 86, 10.1016/j.breast.2006.06.008 Burcombe, 2005, Evaluation of ER, PgR ,HER-2 and Ki-67 as predictor of response to neoadjuvant anthraycycline chemotherapy for operable breast cancer, Br J Cancer, 92, 147, 10.1038/sj.bjc.6602256 Amat, 2005, High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer, Breast Cancer Res Treat, 94, 255, 10.1007/s10549-005-9008-8 Jones, 2006, Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma, Br J Cancer, 94, 358, 10.1038/sj.bjc.6602950 Klauber-DeMore, 2006, Size of residual lymph nodes metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic, Ann Surg Oncol, 13, 685, 10.1245/ASO.2006.03.010 von Minckwitz, 2005, Every 3 weekly doxorubicin with cyclophosphamide followed by docetaxel versus every 2 weekly doxorubicin and docetaxel as preoperative treatment in operable breast cancer: comparative toxicity and efficacy on locoregional disease, J Clin Oncol, 23, 2676, 10.1200/JCO.2005.05.078 Manton, 2006, Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy, Br J Cancer, 94, 427, 10.1038/sj.bjc.6602948 Essermann, 1999, Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging, J Clin Oncol, 17, 110, 10.1200/JCO.1999.17.1.110 Peintinger, 2006, Accuracy of the combination of mammography and sonography in predicting tumor response and breast cancer patients after neoadjuvant chemotherapy, Ann Surg Oncol, 13, 1443, 10.1245/s10434-006-9086-9 Chagpar, 2006, Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy, Ann Surg, 243, 257, 10.1097/01.sla.0000197714.14318.6f Partridge, 2002, Accuracy of MRI imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy, AJR Am J Roentgenenol, 179, 1193, 10.2214/ajr.179.5.1791193 Zangheri, 2004, PET/CT and breast cancer, Eur J Nucl Med Mol Imaging, 31, S135, 10.1007/s00259-004-1536-7 Mankoff, 2005, Changes in glucose metabolism and blood flow following chemotherapy for breast cancer, PET Clin, 1, 71, 10.1016/j.cpet.2005.09.001 Rousseau, 2006, Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18F] fluorodeoxyglucose positron emission tomography, J Clin Oncol, 24, 5366, 10.1200/JCO.2006.05.7406 Chen, 2004, Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy, Acad Radiol, 11, 1115, 10.1016/j.acra.2004.07.007 Wasser, 2003, Evaluation of neoadjuvat chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution, Eur Radiol, 13, 80, 10.1007/s00330-002-1654-1 Mardor, 2003, Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging, J Clin Oncol, 15, 1094, 10.1200/JCO.2003.05.069 Taghian, 2005, Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical Implications, J Clin Oncol, 23, 1951, 10.1200/JCO.2005.08.119 Senofsky, 1998, Local excision, lumpectomy, and quadrantectomy. Surgical considerations, 129 Loibl, 2006, Surgical procedures after neoadjuvant chemotherapy in operable breast cancer—results of the GEPARDUO trial, Ann Surg Oncol, 13, 1434, 10.1245/s10434-006-9011-2 Sadetzky, 2005, Breast Conservation after neoadjuvant chemotherapy, Ann Surg Oncol, 12, 1 Chen, 2005, Breast conservation after neoadjuvant chemotherapy, Cancer, 103, 689, 10.1002/cncr.20815 Kaufmann, 2003, International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations, J Clin Oncol, 21, 2600, 10.1200/JCO.2003.01.136 Kim, 2006, Lymphatic mapping and sentinel lymph node biopsy in early–stage breast carcinoma: a metaanalysis, Cancer, 106, 4, 10.1002/cncr.21568 Mamounas, 2005, Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer—results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol, 23, 2694, 10.1200/JCO.2005.05.188 Xing, 2006, Meta–analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer, Br J Surg, 93, 539, 10.1002/bjs.5209 Kuehn, 2005, A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Consensus Committee of the German Society of Senology, Cancer, 103, 451, 10.1002/cncr.20786 Lyman, 2005, American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer, J Clin Oncol, 23, 7703, 10.1200/JCO.2005.08.001 Clarke, 2005, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15–year survival: an overview of the randomised trials, Lancet, 366, 2087, 10.1016/S0140-6736(05)67887-7 Ring, 2003, Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?, J Clin Oncol, 21, 4540, 10.1200/JCO.2003.05.208 Huang, 2004, Postemastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemothrapy and mastectomy, J Clin Oncol, 22, 4639, 10.1200/JCO.2004.11.129 Garg, 2004, T3 disease at presentation or pathological involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy, Int J Radiat Oncol Biol Phys, 59, 138, 10.1016/j.ijrobp.2003.10.037 Chen, 2004, Breast conservation after neoadjuvant chemotherapy. The MD Anderson experience, J Clin Oncol, 23, 2303, 10.1200/JCO.2004.09.062 Forouhi, 1994, Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment, Br J Surg, 81, 223, 10.1002/bjs.1800810221 Gawne-Cain, 1995, The use of ultrasound for monitoring breast tumour response to pro–adjuvant therapy, Clin Radiol, 50, 681, 10.1016/S0009-9260(05)83312-4 Herrada, 1997, Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma, Clin Cancer Res, 3, 1565 Akashi-Tanaka, 2001, Accuracy of contrast–enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy, Int J Cancer, 96, 66, 10.1002/1097-0215(20010220)96:1<66::AID-IJC7>3.0.CO;2-T Fiorentino, 2001, Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease, Breast Cancer Res Treat, 69, 143, 10.1023/A:1012277325168 Bodini, 2004, Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy, Breast Cancer Res Treat, 85, 211, 10.1023/B:BREA.0000025409.69516.23 Belli, 2006, MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy, Clin Radiol, 61, 946, 10.1016/j.crad.2006.07.004 Akazawa, 2006, Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy, Breast J, 12, 130, 10.1111/j.1075-122X.2006.00220.x Ayers, 2004, Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer, J Clin Oncol, 22, 2284, 10.1200/JCO.2004.05.166 Hannemann, 2005, Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 23, 3331, 10.1200/JCO.2005.09.077 Thuerigen, 2006, Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer, J Clin Oncol, 20, 1839, 10.1200/JCO.2005.04.7019 Hess, 2006, Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer, J Clin Oncol, 24, 4236, 10.1200/JCO.2006.05.6861 Rody, 2005, Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures, Zentralbl Gynakol, 128, 76, 10.1055/s-2006-921508 Chang, 2003, Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer, Lancet, 362, 362, 10.1016/S0140-6736(03)14023-8 Iwao-Koizumi, 2005, Prediction of docetaxel response in human breast cancer by gene expression profiling, J Clin Oncol, 23, 422, 10.1200/JCO.2005.09.078 Cleator, 2006, Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance, Breast Cancer Res Treat, 95, 229, 10.1007/s10549-005-9009-7 Gianni, 2005, Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer, J Clin Oncol, 23, 7265, 10.1200/JCO.2005.02.0818